<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451904</url>
  </required_header>
  <id_info>
    <org_study_id>BAKMAL1407</org_study_id>
    <nct_id>NCT02451904</nct_id>
  </id_info>
  <brief_title>Severe and Cerebral Malaria Investigated Through Host Metabolomics</brief_title>
  <official_title>Microvascular and Metabolic Dysregulation in the Pathogenesis of Severe and Cerebral Malaria Investigated Through Host Metabolomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chittagong Medical College and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The aim is to describe disease mechanisms of severe and cerebral malaria and identify
           new targets for adjunctive therapies.

        -  Despite treatment between 10-30% of patients with severe malaria die.

        -  Metabolic acidosis and cerebral malaria are major complications associated with
           mortality across all age groups. Still, their underlying pathogenesis remains
           incompletely understood.

        -  Using a metabolomics approach, this study aims to characterise the spectrum of acids
           accumulating during acidosis, and investigate patterns of metabolic dysregulation
           associated with coma and seizures.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterisation of patterns of metabolic dysregulation in severe malaria</measure>
    <time_frame>4-6 weeks</time_frame>
    <description>Interrelationship between disturbances in metabolic pathways associated with acidosis and cerebral malaria</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Severe Malaria</condition>
  <arm_group>
    <arm_group_label>Severe/Cerebral Malaria</arm_group_label>
    <description>Intensive monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncomplicated Malaria</arm_group_label>
    <description>Intensive monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis</arm_group_label>
    <description>Intensive monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acidosis</arm_group_label>
    <description>Intensive monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Encephalitis</arm_group_label>
    <description>Intensive monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Individuals</arm_group_label>
    <description>Monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <arm_group_label>Severe/Cerebral Malaria</arm_group_label>
    <arm_group_label>Uncomplicated Malaria</arm_group_label>
    <arm_group_label>Sepsis</arm_group_label>
    <arm_group_label>Acidosis</arm_group_label>
    <arm_group_label>Encephalitis</arm_group_label>
    <arm_group_label>Healthy Individuals</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Urine, CSF, Stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In total, up to 840 patients may be enrolled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Severe/Cerebral Malaria:

          -  Any P. falciparum parasitaemia detected by asexual stages on a peripheral blood-slide
             or a positive rapid diagnostic test in combination with one or more Modified WHO
             Criteria for Severe Malaria (Hien et al, 1996)

          -  &lt; 24 hours after treatment commencement with either parenteral artemisinin or quinine

          -  Age &gt; 12 years

          -  Full informed written consent obtained

        Uncomplicated malaria:

          -  Any level of Plasmodium parasitaemia, detected by asexual stages on a peripheral
             blood-slide or a positive rapid diagnostic test without any of the complications of
             severe malaria stated above.

          -  Age &gt; 12 years

          -  Full informed written consent obtained

        Sepsis:

          -  Clinical signs of infection in combination with any two of the following signs:

               1. Heart rate &gt; 90 beats per minute;

               2. Respiratory rate &gt; 20 breaths per minute, a PaCO2 of &lt; 32 mmHg, or the use of
                  mechanical ventilation for an acute respiratory process;

               3. Tympanic temperature &gt; 38°C or &lt; 36 °C;

               4. White-cell count of &gt; 12x109/L or &lt; 4x109/L, or a differential count showing 10%
                  immature neutrophils ;

          -  Negative peripheral blood slide for any stages of malaria parasites or a negative
             rapid diagnostic test for falciparum and vivax malaria

          -  [As bacterial culture is not routinely available at the study site, positivity of
             cultures is not required]

          -  Age &gt; 12 years

          -  Full informed written consent obtained

        Acidosis:

          -  Clinical suspicion of metabolic acidosis in combination with any of the following:

               1. Peripheral venous bicarbonate &lt; 15 mmol/L

               2. Peripheral venous base excess &lt; -3 mmol/L

          -  Negative peripheral blood slide for any stages of malaria parasites or a negative
             rapid diagnostic test for falciparum and vivax malaria; and not meeting any of the
             inclusion criteria for sepsis as stated above.

          -  Age &gt; 12 years

          -  Full informed written consent obtained

        Encephalitis:

          -  GCS &lt; 11/15

          -  Documented fever &gt; 38°C

          -  Onset of symptoms &lt; 2 weeks, with an indication a lumbar puncture as part of the
             diagnostic work up

          -  Negative peripheral blood slide for any stages of malaria parasites or a negative
             rapid diagnostic test for falciparum and vivax malaria

          -  Age &gt; 12 years

          -  Full informed written consent obtained

        Healthy volunteers:

          -  No chronic or acute disease

          -  No fever in the past 2 weeks

          -  Age &gt; 16 years

          -  Full informed written consent obtained

        Exclusion Criteria:

          -  Known pre-existing chronic medical conditions including advanced hepatic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Arjen M. Dondorp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol Oxford Tropical Medicine Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stije J. Leopold, MD</last_name>
    <phone>+6622036333</phone>
    <email>stije@tropmedres.ac</email>
  </overall_contact>
  <reference>
    <citation>Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005 Aug 27-Sep 2;366(9487):717-25.</citation>
    <PMID>16125588</PMID>
  </reference>
  <reference>
    <citation>Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ; AQUAMAT group. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010 Nov 13;376(9753):1647-57. doi: 10.1016/S0140-6736(10)61924-1. Epub 2010 Nov 7. Erratum in: Lancet. 2011 Jan 8;377(9760):126.</citation>
    <PMID>21062666</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pathogenesis</keyword>
  <keyword>Microvascular function</keyword>
  <keyword>Metabolic dysregulation</keyword>
  <keyword>Metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Cerebral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

